Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Jorge Ramos, DO (Seattle Genetics, Inc)
Corinna Palanca-Wessels, MD, PhD (Seattle Genetics, Inc.)